.svg){kind=icon}
Blog
$name
Rick Johnston, PhD, Senior Software Solutions Principal, Consulting Services, IQVIA
David Wolter, Vice President, Consulting
Alexandra Tataru, MS, MBA, Product Lead, Consulting Services
Jan 08, 2020
- Blogs
- Why Is Forecasting Biosimilar Impact So Difficult
YOU MAY ALSO BE INTERESTED IN
Blog
Commercial forecasting for cell and gene therapies: 4 obstacles to overcome
By:
Rick Johnston, David Wolter, Alexandra Tataru
Blog
Harnessing the Full Power of Your Commercial Forecast
By:
David Wolter, Rick Johnston, Alexandra Tataru
Blog
Commercial pharma forecasts are surprisingly inaccurate: Here are 5 ways to make them better
By:
Rick Johnston, David Wolter, Alexandra Tataru
Prev
Next